

Japan Long-Term Care Pharmaceutical Consumption Market - 2024-2033

<https://marketpublishers.com/r/JF28F45849F7EN.html>

Date: February 2026

Pages: 181

Price: US\$ 2,999.00 (Single User License)

ID: JF28F45849F7EN

Abstracts

The Japan Long-Term Care Pharmaceutical Consumption Market was valued at US\$ 14.3 Billion in 2024 and is anticipated to reach US\$ 24.99 Billion by 2033, at a CAGR of 0.064 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Long-Term Care Pharmaceutical Consumption Market.

This report delivers a comprehensive overview of the Japan Long-Term Care Pharmaceutical Consumption Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Long-Term Care Pharmaceutical Consumption Market. The Japan Long-Term Care Pharmaceutical Consumption Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Long-Term Care Pharmaceutical Consumption Market Scope:

By Drug Type

Prescription (Rx) Generics

Specialty Biologics & Biosimilars

Long-Listed Brands

Over-the-Counter (OTC) & Preventive Medicines

By Therapeutic Area

Central Nervous System (CNS)

Cardiovascular

Metabolic & Anti-Diabetic

Oncology

Infectious Disease & Vaccines

Pain Management & Palliative Care

By Care Delivery Setting

Home Healthcare

Nursing Care & Assisted Living Facilities

Hospice & Palliative Care

Rehabilitation / Post-Acute Care

By Distribution Channel

Hospital Pharmacies

Retail & Community Pharmacies

Institutional LTC Facility Supply

Online & Mail-Order Pharmacies

By Age Group

40–64 Years

65–74 Years

75–84 Years

85+ years

Key Players

Takeda Pharmaceutical Company Limited

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Eisai Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

Sumitomo Pharma Co., Ltd.

Shionogi & Co., Ltd.

Chugai Pharmaceutical Co., Ltd

Pfizer

Kyowa Kirin Co., Ltd.

Major Highlights

This report delivers a comprehensive overview of the Japan Long-Term Care Pharmaceutical Consumption Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Long-Term Care Pharmaceutical Consumption Market. The Japan Long-Term Care Pharmaceutical Consumption Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Growth of Palliative and End-of-Life Care
 - 3.1.1.2. Government Push for Dementia Countermeasures
 - 3.1.1.3. Chronic Infection Control in LTC Facilities
 - 3.1.2. Restraints
 - 3.1.2.1. Stringent Drug Price Revisions under National Health Insurance
 - 3.1.2.2. Polypharmacy Reduction Policies & Deprescribing Initiatives
 - 3.1.3. Opportunity
 - 3.1.3.1. Growth of Personalized & Precision Geriatric Medicine
 - 3.1.3.2. Preventive Therapeutics for Frailty & Mobility Preservation
 - 3.1.3.3. Expansion of Home-Based Medical & Pharmaceutical Services
 - 3.1.4. Trends
 - 3.1.4.1. Deprescribing & Rational Polypharmacy Management
 - 3.1.4.2. Shift Toward Home & Community-Based Care
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

- 4.1. Porter's Five Force Analysis – Japan Long-Term Care Pharmaceutical Consumption Market
- 4.2. Geopolitical & Supply Chain Exposure
- 4.3. Social & Patient-Centric Factors
- 4.4. Economic Factors
- 4.5. Pricing Analysis
- 4.6. Regulatory Analysis
- 4.7. Go-To-Market (GTM) Strategy
- 4.8. Innovation & R&D Trends
- 4.9. Sustainability and ESG Analysis
- 4.10. Polypharmacy & Chronic Medication Management in LTC
- 4.11. Buyer Decision Criteria & Adoption Drivers
- 4.12. DMI Opinion – Strategic Outlook for the Japan Long-Term Care Pharmaceutical Consumption Market

5. BY DRUG TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
 - 5.1.2. Market Attractiveness Index, By Drug Type
- 5.2. Prescription (Rx) Generics
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Specialty Biologics & Biosimilars
- 5.4. Long-Listed Brands
- 5.5. Over-the-Counter (OTC) & Preventive Medicines

6. BY THERAPEUTIC AREA

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 6.1.2. Market Attractiveness Index, By Therapeutic Area
- 6.2. Central Nervous System (CNS)
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Cardiovascular

- 6.4. Metabolic & Anti-Diabetic
- 6.5. Oncology
- 6.6. Infectious Disease & Vaccines
- 6.7. Pain Management & Palliative Care

7. BY CARE DELIVERY SETTING

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Delivery Setting
 - 7.1.2. Market Attractiveness Index, By Care Delivery Setting
- 7.2. Home Healthcare
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Nursing Care & Assisted Living Facilities
- 7.4. Hospice & Palliative Care
- 7.5. Rehabilitation / Post-Acute Care

8. BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail & Community Pharmacies
- 8.4. Institutional LTC Facility Supply
- 8.5. Online & Mail-Order Pharmacies

9. BY AGE GROUP

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 9.1.2. Market Attractiveness Index, By Age Group
- 9.2. 40–64 Years
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. 65–74 Years
- 9.4. 75–84 Years

9.5. 85+ years

10. COMPETITIVE LANDSCAPE ANALYSIS

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 10.4. Partner Identification Analysis
- 10.5. Investment & Funding Landscape
- 10.6. Strategic Alliances & Innovation Pipelines

11. COMPANY PROFILES

- 11.1. Takeda Pharmaceutical Company Limited
 - 11.1.1. Company Overview
 - 11.1.2. Drug Type Portfolio
 - 11.1.3. Revenue Analysis
 - 11.1.4. Pricing Analysis
 - 11.1.5. SWOT Analysis
 - 11.1.6. Recent Developments
 - 11.1.6.1. Major Deals
 - 11.1.6.2. M&A
 - 11.1.6.3. Collaboration
 - 11.1.6.4. Acquisition
 - 11.1.6.5. Joint Ventures
 - 11.1.6.6. Innovations
 - 11.1.7. Recent News
 - 11.1.7.1. Events
 - 11.1.7.2. Conferences
 - 11.1.7.3. Symposiums
 - 11.1.7.4. Webinars
- 11.2. Daiichi Sankyo Company, Limited
- 11.3. Astellas Pharma Inc.
- 11.4. Eisai Co., Ltd.
- 11.5. Otsuka Pharmaceutical Co., Ltd.
- 11.6. Sumitomo Pharma Co., Ltd.
- 11.7. Shionogi & Co., Ltd.
- 11.8. Chugai Pharmaceutical Co., Ltd
- 11.9. Pfizer

11.10. Kyowa Kirin Co., Ltd. (LIST NOT EXHAUSTIVE)

12. JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET – RESEARCH METHODOLOGY

12.1. Research Data

12.1.1. Secondary Data

12.1.2. Primary Data

12.1.3. CAGR Analysis

12.2. Market Size Estimation Methodology

12.2.1. Bottom-Up Approach

12.2.2. Top-Down Approach

12.3. Market Breakdown & Data Triangulation

12.4. Research Assumptions

12.5. Limitations

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Japan Long-Term Care Pharmaceutical Consumption Market - 2024-2033

Product link: <https://marketpublishers.com/r/JF28F45849F7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JF28F45849F7EN.html>